AAAAAA

   
Results: 1-24 |
Results: 24
Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors
Authors: Miller, CW Ikezoe, T Krug, U Hofmann, WK Tavor, S Vegesna, V Tsukasaki, K Takeuchi, S Koeffler, HP
Citation: Cw. Miller et al., Mutations of the CHK2 gene are found in some osteosarcomas, but are rare in breast, lung, and ovarian tumors, GENE CHROM, 33(1), 2002, pp. 17-21
Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma
Authors: Hofmann, WK Tsukasaki, K Takeuchi, N Takeuchi, S Koeffler, HP
Citation: Wk. Hofmann et al., Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma, LEUK LYMPH, 42(5), 2001, pp. 1107-1109
Analysis of the CHK2 gene in lymphoid malignancies
Authors: Tavor, S Takeuchi, S Tsukasaki, K Miller, CW Hofmann, WK Ikezoe, T Said, JW Koeffler, HP
Citation: S. Tavor et al., Analysis of the CHK2 gene in lymphoid malignancies, LEUK LYMPH, 42(3), 2001, pp. 517-520
Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34(+) cell expansion and maturation
Authors: Koschmieder, S Bug, G Schroder, B Rossmanith, T Hofmann, WK Kalina, U Hoelzer, D Ottmann, OG
Citation: S. Koschmieder et al., Murine M2-10B4 and SL/SL cell lines differentially affect the balance between CD34(+) cell expansion and maturation, INT J HEMAT, 73(1), 2001, pp. 71-77
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34(+) cells from healthy donors, but not from patients with AML after MDS
Authors: Koschmieder, S Hofmann, WK Kunert, J Wagner, S Ballas, K Seipelt, G Hoelzer, D Ottmann, OG Kalina, U
Citation: S. Koschmieder et al., TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34(+) cells from healthy donors, but not from patients with AML after MDS, LEUKEMIA, 15(6), 2001, pp. 942-949
Transforming growth factor-beta(1) interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells
Authors: Kalina, U Koschmieder, S Hofmann, WK Wagner, S Kauschat, D Hoelzer, D Ottmann, OG
Citation: U. Kalina et al., Transforming growth factor-beta(1) interferes with thrombopoietin-induced signal transduction in megakaryoblastic and erythroleukemic cells, EXP HEMATOL, 29(5), 2001, pp. 602-608
Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias
Authors: Hofmann, WK Miller, CW Tsukasaki, K Tavor, S Ikezoe, T Hoelzer, D Takeuchi, S Koeffler, HP
Citation: Wk. Hofmann et al., Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias, LEUK RES, 25(4), 2001, pp. 333-338
Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes
Authors: Hofmann, WK Takeuchi, S Xie, D Miller, CW Hoelzer, D Koeffler, HP
Citation: Wk. Hofmann et al., Frequent loss of heterozygosity in the region of D1S450 at 1p36.2 in myelodysplastic syndromes, LEUK RES, 25(10), 2001, pp. 855-858
Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray
Authors: Hofmann, WK de Vos, S Tsukasaki, K Wachsman, W Pinkus, GS Said, JW Koeffler, HP
Citation: Wk. Hofmann et al., Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, BLOOD, 98(3), 2001, pp. 787-794
Defective megakaryocytic development in myelodysplastic syndromes
Authors: Hofmann, WK Kalina, U Koschmieder, S Seipelt, G Hoelzer, D Ottmann, OG
Citation: Wk. Hofmann et al., Defective megakaryocytic development in myelodysplastic syndromes, LEUK LYMPH, 38(1-2), 2000, pp. 13-19
Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein binding (vol 36, pg 103, 1999)
Authors: Hofmann, WK
Citation: Wk. Hofmann, Modulation of vincristine cytotoxicity by dexverapamil in sensitive and resistant HL-60 cell lines as a function of extracellular protein binding (vol 36, pg 103, 1999), INT J CL PH, 38(1), 2000, pp. 46-46
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
Authors: Hofmann, WK Seipelt, G Ottmann, OG Kalina, U Koschmieder, S Brucher, J Frickhofen, N Klausmann, M Mitrou, PS Hoelzer, D
Citation: Wk. Hofmann et al., Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels, ANN HEMATOL, 79(5), 2000, pp. 255-258
Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study
Authors: Hofmann, WK Kell, WJ Fenaux, P Castaigne, S Ganser, A Chomienne, C Burnett, R Kowal, C Hoelzer, D Burnett, AK
Citation: Wk. Hofmann et al., Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study, LEUKEMIA, 14(9), 2000, pp. 1583-1588
Allelotype analysis of the myelodysplastic syndrome
Authors: Xie, D Hofmann, WK Mori, N Miller, CW Hoelzer, D Koeffler, HP
Citation: D. Xie et al., Allelotype analysis of the myelodysplastic syndrome, LEUKEMIA, 14(5), 2000, pp. 805-810
New aspects of the treatment of patients with low-risk myelodysplastic syndromes
Authors: Hofmann, WK Seipelt, G Kalina, U Hoelzer, D
Citation: Wk. Hofmann et al., New aspects of the treatment of patients with low-risk myelodysplastic syndromes, ONKOLOGIE, 23(1), 2000, pp. 12-16
Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes
Authors: Kalina, U Hofmann, WK Koschmieder, S Wagner, S Kauschat, D Hoelzer, D Ottmann, OG
Citation: U. Kalina et al., Alteration of c-mpl-mediated signal transduction in CD34(+) cells from patients with myelodysplastic syndromes, EXP HEMATOL, 28(10), 2000, pp. 1158-1163
Platelet glycoprotein expression in patients with myelodysplastic syndrome
Authors: Seidl, C Siehl, J Ganser, A Hofmann, WK Fischer, M Kirchmaier, CM Hoelzer, D Seifried, E
Citation: C. Seidl et al., Platelet glycoprotein expression in patients with myelodysplastic syndrome, THROMB RES, 100(1), 2000, pp. 27-34
IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 andby the extracellular regulated kinases p44(erk-1) and p42(erk-21)
Authors: Kalina, U Kauschat, D Koyama, N Nuernberger, H Ballas, K Koschmieder, S Bug, G Hofmann, WK Hoelzer, D Ottmann, OG
Citation: U. Kalina et al., IL-18 activates STAT3 in the natural killer cell line 92, augments cytotoxic activity, and mediates IFN-gamma production by the stress kinase p38 andby the extracellular regulated kinases p44(erk-1) and p42(erk-21), J IMMUNOL, 165(3), 2000, pp. 1307-1313
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
Authors: Hofmann, WK Ganser, A Seipelt, G Ottmann, OG Zander, C Geissler, G Hoffmann, K Hoffken, K Fischer, JT Isele, G Hoelzer, D
Citation: Wk. Hofmann et al., Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor, ANN HEMATOL, 78(3), 1999, pp. 125-130
Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha
Authors: Hofmann, WK Kalina, U Seipelt, G Hoffmann, K Wagner, S Hoelzer, D Ottmann, OG
Citation: Wk. Hofmann et al., Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha, EUR J HAEMA, 62(5), 1999, pp. 336-340
Clinical use of thrombopoietin
Authors: Ottmann, OG Hoelzer, D Hofmann, WK
Citation: Og. Ottmann et al., Clinical use of thrombopoietin, LEUKEMIA, 13(9), 1999, pp. 1471-1472
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Authors: Hofmann, WK Ottmann, OG Hoelzer, D
Citation: Wk. Hofmann et al., Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?, LEUKEMIA, 13(1), 1999, pp. 14-18
Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Authors: Hofmann, WK Ottmann, OG Hoelzer, D
Citation: Wk. Hofmann et al., Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?, LEUKEMIA, 13, 1999, pp. S14-S18
Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes
Authors: Hofmann, WK Kalina, U Wagner, S Seipelt, G Ries, C Hoelzer, D Ottmann, OG
Citation: Wk. Hofmann et al., Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes, EXP HEMATOL, 27(3), 1999, pp. 395-400
Risultati: 1-24 |